Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | 0.00% | -28.57% | -44.44% |
Mar. 25 | Oncosil Medical Issues Non-Renounceable Entitlement Offer Prospectus | MT |
Mar. 20 | Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer | MT |
Sales 2022 | 1.06M 693K | Sales 2023 | 1.47M 956K | Capitalization | 23.71M 15.45M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.52M | Net income 2023 | -11M -7.17M | EV / Sales 2022 | 27 x |
Net cash position 2022 | 10.98M 7.15M | Net cash position 2023 | 9.22M 6.01M | EV / Sales 2023 | 9.87 x |
P/E ratio 2022 |
-3.02
x | P/E ratio 2023 |
-1.2
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.22% |
1 week | -28.57% | ||
Current month | -37.50% | ||
1 month | -37.50% | ||
3 months | -44.44% | ||
6 months | -44.44% | ||
Current year | -44.44% |
Managers | Title | Age | Since |
---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Christian Cin
DFI | Director of Finance/CFO | - | 23-05-31 |
Jon Bell
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Douglas Cubbin
CHM | Chairman | - | 23-08-06 |
Director/Board Member | - | 23-07-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 0.005 | 0.00% | 660 000 |
24-03-27 | 0.005 | -16.65% | 2,327,785 |
24-03-26 | 0.005999 | 0.00% | 704,910 |
24-03-25 | 0.005999 | 0.00% | 2,066,536 |
24-03-22 | 0.005999 | -14.30% | 917,406 |
Delayed Quote Australian S.E., March 27, 2024 at 07:06 pm EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.44% | 6.44M | |
+9.29% | 45.97B | |
+52.73% | 43.93B | |
+7.31% | 42.34B | |
-8.78% | 28.27B | |
+18.51% | 27.18B | |
-21.70% | 19.44B | |
+14.64% | 13.83B | |
+32.17% | 12.4B | |
+5.08% | 11.45B |